Champions Oncology Inc (NASDAQ:CSBR) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019. Champions Oncology Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Champions Oncology Inc has a market cap of $76.990 million; its shares were traded at around $6.63 with a P/E ratio of 663.00 and P/S ratio of 3.03.
For the last quarter Champions Oncology Inc reported a revenue of $7.72 million, compared with the revenue of $4.92 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $27.1 million, an increase of 33.7% from last year. For the complete 30-year financial data, please go here.. For the last five years Champions Oncology Inc had an average revenue growth rate of 22.3% a year.
The reported diluted earnings per share was 1 cents for the year, compared with the loss per share of $2.2 in the previous year. The Champions Oncology Inc had an operating margin of 0.85%, compared with the operating margin of -7.13% a year before. The 10-year historical median operating margin of Champions Oncology Inc is -67.29%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Champions Oncology Inc has the cash and cash equivalents of $3.24 million, compared with $0.86 million in the previous year. The company had no long term debt. Champions Oncology Inc has a financial strength rank of 8 (out of 10).
At the current stock price of $6.63, Champions Oncology Inc is traded at 28% discount to its historical median P/S valuation band of $9.21. The P/S ratio of the stock is 3.03, while the historical median P/S ratio is 4.20. The stock lost 24.73% during the past 12 months.
For the complete 20-year historical financial data of CSBR, click here.
This article first appeared on GuruFocus.